{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:47:18Z","timestamp":1788353238477,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10792-021-02198-x","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T19:03:36Z","timestamp":1642705416000},"page":"2017-2028","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence"],"prefix":"10.1007","volume":"42","author":[{"given":"Kaveh","family":"Fadakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8829-053X","authenticated-orcid":false,"given":"Mohammadreza","family":"Mehrabi Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Riazi-Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Azarkish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsar Dastjani","family":"Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Bazvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"2198_CR1","unstructured":"Gillbert C, Muhit M (2008) Twenty years of childhood blindness: What have we learnt? Community Eye Heal J. 21(67):46\u201347. Accessed December 16, 2020. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2580065\/"},{"issue":"26","key":"2198_CR2","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","volume":"367","author":"ME Hartnett","year":"2012","unstructured":"Hartnett ME, Penn JS (2012) Mechanisms and management of retinopathy of prematurity. N Engl J Med 367(26):2515\u20132526. https:\/\/doi.org\/10.1056\/NEJMra1208129","journal-title":"N Engl J Med"},{"key":"2198_CR3","unstructured":"Good WV, Group ET for R of PC (2004) Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 102:233\u2013250. https:\/\/pubmed.ncbi.nlm.nih.gov\/15747762"},{"issue":"11","key":"2198_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132(11):1327\u20131333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2772","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"2198_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"issue":"9","key":"2198_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","volume":"2","author":"R Roohipoor","year":"2018","unstructured":"Roohipoor R, Karkhaneh R, Riazi-Esfahani M et al (2018) Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmol Retin 2(9):942\u2013948. https:\/\/doi.org\/10.1016\/j.oret.2018.01.017","journal-title":"Ophthalmol Retin"},{"issue":"6","key":"2198_CR7","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","volume":"10","author":"L Pertl","year":"2015","unstructured":"Pertl L, Steinwender G, Mayer C et al (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One 10(6):e0129383. https:\/\/doi.org\/10.1371\/journal.pone.0129383","journal-title":"PLoS One"},{"key":"2198_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/IMCRJ.S258881","volume":"13","author":"F Bazvand","year":"2020","unstructured":"Bazvand F, Pour EK, Gharehbaghi G et al (2020) Hypertension and ischemic stroke after aflibercept for retinopathy of prematurity. Int Med Case Rep J 13:243\u2013247. https:\/\/doi.org\/10.2147\/IMCRJ.S258881","journal-title":"Int Med Case Rep J"},{"issue":"1","key":"2198_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40942-020-00276-3","volume":"7","author":"F Bazvand","year":"2021","unstructured":"Bazvand F, Riazi-Esfahani H, Mirshahi A et al (2021) Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors. Int J Retin Vitr 7(1):5. https:\/\/doi.org\/10.1186\/s40942-020-00276-3","journal-title":"Int J Retin Vitr"},{"issue":"5","key":"2198_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 122(5):1008\u20131015. https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.017","journal-title":"Ophthalmology"},{"issue":"8","key":"2198_CR11","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/archophthalmol.2010.145","volume":"128","author":"QV Hoang","year":"2010","unstructured":"Hoang QV, Kiernan DF, Chau FY, Shapiro MJ, Blair MP (2010) Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment. Arch Ophthalmol 128(8):1080\u20131081. https:\/\/doi.org\/10.1001\/archophthalmol.2010.145","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"2198_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3928\/23258160-20170301-10","volume":"48","author":"AR Hajrasouliha","year":"2017","unstructured":"Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, Yoon H, Blair MP (2017) Reactivation of retinopathy of prematurity three years after treatment with bevacizumab. Ophthalmic Surg Lasers Imaging Retina 48(3):255\u2013259. https:\/\/doi.org\/10.3928\/23258160-20170301-10","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"9","key":"2198_CR13","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123(9):1845\u20131855. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology"},{"issue":"9","key":"2198_CR14","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","volume":"40","author":"KP Ling","year":"2020","unstructured":"Ling KP, Liao PJ, Wang NK et al (2020) Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina 40(9):1793\u20131803. https:\/\/doi.org\/10.1097\/IAE.0000000000002663","journal-title":"Retina"},{"issue":"4","key":"2198_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00417-020-04605-y","volume":"258","author":"MA Mart\u00ednez-Castellanos","year":"2020","unstructured":"Mart\u00ednez-Castellanos MA, Gonz\u00e1lez-H Le\u00f3n A, Romo-Aguas JC, Gonzalez-Gonzalez LA (2020) A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series. Graefe\u2019s Arch Clin Exp Ophthalmol = Albr von Graefes Arch fur Klin und Exp Ophthalmol 258(4):767\u2013772. https:\/\/doi.org\/10.1007\/s00417-020-04605-y","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol = Albr von Graefes Arch fur Klin und Exp Ophthalmol"},{"key":"2198_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039","volume":"198","author":"TA Chen","year":"2019","unstructured":"Chen TA, Shields RA, Bodnar ZH, Callaway NF, Schachar IH, Moshfeghi DM (2019) A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity. Am J Ophthalmol 198:63\u201369. https:\/\/doi.org\/10.1016\/j.ajo.2018.09.039","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2198_CR17","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M et al (2016) Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol 94(6):e417\u2013e420. https:\/\/doi.org\/10.1111\/aos.13008","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"2198_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3928\/23258160-20160229-12","volume":"47","author":"LL Snyder","year":"2016","unstructured":"Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP (2016) Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 47(3):280\u2013283. https:\/\/doi.org\/10.3928\/23258160-20160229-12","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"8","key":"2198_CR19","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol (Chicago, Ill 1960) 130(8):1000\u20131006. https:\/\/doi.org\/10.1001\/archophthalmol.2012.592","journal-title":"Arch Ophthalmol (Chicago, Ill 1960)"},{"issue":"6","key":"2198_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamaophthalmol.2016.0611","volume":"134","author":"JP Campbell","year":"2016","unstructured":"Campbell JP, Ataer-Cansizoglu E, Bolon-Canedo V et al (2016) Expert diagnosis of plus disease in retinopathy of prematurity from computer-based image analysis. JAMA Ophthalmol 134(6):651\u2013657. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.0611","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"2198_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep27082","volume":"6","author":"JJT Chan","year":"2016","unstructured":"Chan JJT, Lam CPS, Kwok MKM et al (2016) Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. Sci Rep 6(1):1\u20137. https:\/\/doi.org\/10.1038\/srep27082","journal-title":"Sci Rep"},{"issue":"2","key":"2198_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0161-6420(93)31665-9","volume":"100","author":"DB Schaffer","year":"1993","unstructured":"Schaffer DB, Palmer EA, Plotsky DF et al (1993) Prognostic factors in the natural course of retinopathy of prematurity. Ophthalmology 100(2):230\u2013237. https:\/\/doi.org\/10.1016\/S0161-6420(93)31665-9","journal-title":"Ophthalmology"},{"issue":"6","key":"2198_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.5455\/medarh.2015.69.409-413","volume":"69","author":"J Alajbegovic-Halimic","year":"2015","unstructured":"Alajbegovic-Halimic J, Zvizdic D, Alimanovic-Halilovic E, Dodik I, Duvnjak S (2015) Risk factors for retinopathy of prematurity in premature born children. Med Arch (Sarajevo, Bosnia Herzegovina) 69(6):409\u2013413. https:\/\/doi.org\/10.5455\/medarh.2015.69.409-413","journal-title":"Med Arch (Sarajevo, Bosnia Herzegovina)"},{"issue":"9\u201310","key":"2198_CR24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1177\/1120672103013009-1009","volume":"13","author":"K Allegaert","year":"2003","unstructured":"Allegaert K, Casteels I, Cossey V, Devlieger H (2003) Retinopathy of prematurity: any difference in risk factors between a high and low risk population? Eur J Ophthalmol 13(9\u201310):784\u2013788. https:\/\/doi.org\/10.1177\/1120672103013009-1009","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"2198_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/IAE.0000000000000270","volume":"35","author":"YH Chen","year":"2015","unstructured":"Chen YH, Lien RI, Tsai S et al (2015) Natural history of retinopathy of prematurity: two-year outcomes of a prospective study. Retina 35(1):141\u2013148. https:\/\/doi.org\/10.1097\/IAE.0000000000000270","journal-title":"Retina"},{"issue":"10","key":"2198_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.earlhumdev.2011.05.003","volume":"87","author":"V Giapros","year":"2011","unstructured":"Giapros V, Drougia A, Asproudis I, Theocharis P, Andronikou S (2011) Low gestational age and chronic lung disease are synergistic risk factors for retinopathy of prematurity. Early Hum Dev 87(10):653\u2013657. https:\/\/doi.org\/10.1016\/j.earlhumdev.2011.05.003","journal-title":"Early Hum Dev"},{"issue":"3","key":"2198_CR27","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1167\/iovs.16-20680","volume":"58","author":"J Lyu","year":"2017","unstructured":"Lyu J, Zhang Q, Chen C-LL et al (2017) Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors. Invest Ophthalmol Vis Sci 58(3):1719\u20131725. https:\/\/doi.org\/10.1167\/iovs.16-20680","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2198_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/5078565","volume":"2017","author":"Q Hu","year":"2017","unstructured":"Hu Q, Bai Y, Chen X, Huang L, Chen Y, Li X (2017) Recurrence of retinopathy of prematurity in zone II stage 3+ after ranibizumab treatment: a retrospective study. J Ophthalmol 2017:1\u20135. https:\/\/doi.org\/10.1155\/2017\/5078565","journal-title":"J Ophthalmol"},{"issue":"10","key":"2198_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.oret.2020.04.022","volume":"4","author":"RY Choi","year":"2020","unstructured":"Choi RY, Brown JM, Kalpathy-Cramer J et al (2020) Variability in plus disease identified using a deep learning-based retinopathy of prematurity severity scale. Ophthalmol Retina 4(10):1016\u20131021. https:\/\/doi.org\/10.1016\/j.oret.2020.04.022","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"2198_CR30","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/jamaophthalmol.2019.2433","volume":"137","author":"S Taylor","year":"2019","unstructured":"Taylor S, Brown JM, Gupta K et al (2019) Monitoring disease progression with a quantitative severity scale for retinopathy of prematurity Using deep learning. JAMA Ophthalmol 137(9):1022\u20131028. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.2433","journal-title":"JAMA Ophthalmol"},{"key":"2198_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.10.025","author":"JP Campbell","year":"2020","unstructured":"Campbell JP, Kim SJ, Brown JM et al (2020) Evaluation of a novel retinopathy of prematurity severity scale applied by clinicians and deep learning. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2020.10.025","journal-title":"Ophthalmology"},{"issue":"4","key":"2198_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/archopht.1956.00930040489001","volume":"56","author":"VE Kinsey","year":"1956","unstructured":"Kinsey VE (1956) Retrolental fibroplasia; cooperative study of retrolental fibroplasia and the use of oxygen. AMA Arch Ophthalmol 56(4):481\u2013543","journal-title":"AMA Arch Ophthalmol"},{"issue":"16","key":"2198_CR33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJM199204163261603","volume":"326","author":"JT Flynn","year":"1992","unstructured":"Flynn JT, Bancalari E, Snyder ES et al (1992) A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 326(16):1050\u20131054. https:\/\/doi.org\/10.1056\/NEJM199204163261603","journal-title":"N Engl J Med"},{"issue":"8988","key":"2198_CR34","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/S0140-6736(95)92475-2","volume":"346","author":"S Cunningham","year":"1995","unstructured":"Cunningham S, Mclntosh N, Fleck BW, Elton RA (1995) Transcutaneous oxygen levels in retinopathy of prematurity. Lancet 346(8988):1464\u20131465. https:\/\/doi.org\/10.1016\/S0140-6736(95)92475-2","journal-title":"Lancet"},{"issue":"4","key":"2198_CR35","first-page":"307","volume":"39","author":"E Bossi","year":"1984","unstructured":"Bossi E, Koerner F, Flury B, Zulauf M (1984) Retinopathy of prematurity: a risk factor analysis with univariate and multivariate statistics. Helv Paediatr Acta 39(4):307\u2013317","journal-title":"Helv Paediatr Acta"},{"issue":"22","key":"2198_CR36","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1056\/nejmoa1302298","volume":"368","author":"BJ Stenson","year":"2013","unstructured":"BOOST II United Kingdom Collaborative Group, BOOST II Australia Collaborative Group, BOOST II New Zealand Collaborative Group, Stenson BJ, Tarnow-Mordi WO, Darlow BA, et al. (2013) Oxygen Saturation and Outcomes in Preterm Infants. N Engl J Med 368(22):2094\u20132104. https:\/\/doi.org\/10.1056\/nejmoa1302298","journal-title":"N Engl J Med"},{"issue":"4","key":"2198_CR37","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1542\/peds.2004-1309","volume":"115","author":"BA Darlow","year":"2005","unstructured":"Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ (2005) Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand neonatal network. Pediatrics 115(4):990\u2013996. https:\/\/doi.org\/10.1542\/peds.2004-1309","journal-title":"Pediatrics"},{"issue":"3","key":"2198_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.18502\/jovr.v14i3.4785","volume":"14","author":"M Zarei","year":"2019","unstructured":"Zarei M, Bazvand F, Ebrahimiadib N et al (2019) Prevalence and risk factors of retinopathy of prematurity in Iran. J Ophthalmic Vis Res 14(3):291\u2013298. https:\/\/doi.org\/10.18502\/jovr.v14i3.4785","journal-title":"J Ophthalmic Vis Res"},{"issue":"4","key":"2198_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/ANC.0b013e318225a332","volume":"11","author":"AJ Mitchell","year":"2011","unstructured":"Mitchell AJ, Green A, Jeffs DA, Roberson PK (2011) Physiologic effects of retinopathy of prematurity screening examinations. Adv Neonatal Care 11(4):291\u2013297. https:\/\/doi.org\/10.1097\/ANC.0b013e318225a332","journal-title":"Adv Neonatal Care"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02198-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-02198-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02198-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T13:41:46Z","timestamp":1657892506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-02198-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2198"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-02198-x","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"3 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Human subjects were included in this study. The ethics committee of eye research center, Farabi Eye Hospital, approved this study ().","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was conducted according to the tenets of the Declaration of Helsinki. Any procedure was done after providing parents with informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s parents (that his fundus photographs were used in the Figue1) for publication of any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}